Q BioMed, a biotechnology acceleration company, has announced that Mannin Research, its research partner for the development of a novel pharmaceutical eye-drop to treat primary open-angle glaucoma utilizing the Tie2 Mechanism of Action, has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto.

Q BioMed focuses on acquiring companies and biomedical assets, providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, and enabling them to provide products to patients in need?.

JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

Mannin will utilize JLABS @ Toronto as complementary lab space to conduct commercial research and development as it relates to its MAN-01 program for Glaucoma and to the greater Tie2 platform technology. As a resident, Mannin will have access to the development and commercialization expertise provided by JLABS @ Toronto.

Mannin’s chief executive officer, Dr. George N. Nikopoulos stated, “We are excited to be apart of JLABS @ Toronto. We see tremendous value in being a part of the JLABS network.  We are also excited to increase our footprint within the Toronto biotechnology cluster as a global company working to make positive local impacts in the communities where we operate.”